Letermovir

CAS 917389-32-3 7 FDA-DMF suppliersSmall Molecule

Overview

Letermovir is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1241951).

API suppliers (3)

Suppliers of Letermovir backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

  • Zhejiang Hisun Pharmaceutical Co., Ltd.China2 active DMF
  • Taiji Biopharmaceuticals Pvt. Ltd.India1 active DMF
  • Taiji Biopharmaceuticals Pvt. Ltd.India1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (6 approved US products), the latest listed US patent on Letermovir expires 28 Feb 2033 and exclusivity 29 Aug 2031. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name
2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
Canonical SMILES
COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
InChIKey
FWYSMLBETOMXAG-QHCPKHFHSA-N

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo